Clinical Trials and Developments - Adicet plans to initiate a Phase 1 clinical trial for ADI-001 in lupus nephritis in Q2 2024, following FDA clearance of its IND application in December 2023[2] - Adicet presented promising preclinical data for ADI-270 at the ASGCT Annual Meeting, with plans to submit an IND for renal cell carcinoma in Q2 2024[4] - The company is continuing to enroll patients in the ongoing Phase 1 study of ADI-001 for relapsed or refractory non-Hodgkin's lymphoma, with a clinical update expected in the second half of 2024[5] - Adicet aims to expand ADI-001's clinical applications to additional autoimmune diseases, with preliminary data expected in late 2024 or early 2025[3] Financial Performance - The net loss for Q1 2024 was $28.0 million, or $0.35 per share, compared to a net loss of $30.9 million, or $0.72 per share, in Q1 2023[7] - R&D expenses for Q1 2024 were $23.9 million, a decrease of 11% from $26.8 million in Q1 2023, primarily due to reduced expenses related to contract development manufacturing organizations[6] - Total operating expenses for Q1 2024 were $30.9 million, down from $33.3 million in Q1 2023[14] - The company reported interest income of $2.9 million for Q1 2024, compared to $2.7 million in Q1 2023[14] Cash and Assets - Cash and cash equivalents stood at $247.6 million as of March 31, 2024, an increase from $231.6 million in the same period last year, expected to fund operations into the second half of 2026[7] - Total assets increased to $293.1 million as of March 31, 2024, up from $207.3 million at the end of 2023[15]

Company Overview - Adicet Bio, Inc. (ACET) is positioned well within the Medical - Biomedical and Genetics sector, which is currently experiencing positive earnings estimate revisions [1][2] - The company has seen a narrowing of loss estimates, with current quarter estimates improving from a loss of $0.38 per share to a loss of $0.35 per share, and current year estimates improving from a loss of $1.81 per share to a loss of $1.72 per share [2] Industry Insights - The Medical - Biomedical and Genetics industry has a Zacks Industry Rank of 74 out of over 250 industries, indicating a strong position relative to other sectors [1] - The positive trends in the industry suggest that a rising tide may benefit multiple companies within this segment, enhancing the investment appeal of Adicet Bio [1]

Adicet Bio, Inc. (ACET) has been beaten down lately with too much selling pressure. While the stock has lost 16.4% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier.Guide to Identifying Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator ...

Adicet Bio (NASDAQ:ACET) just reported results for the fourth quarter of 2023.Adicet Bio reported earnings per share of -69 cents. This met the analyst estimate for EPS of -69 cents.The company did not report any revenue for the quarter.InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-38359 Adicet Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 81-3305277 (State or other jurisdiction of (I.R.S ...

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the fourth quarter and year ended December 31, 2023. “We are excited to explore the potential of our gamma delta T cell platform in autoimmune diseases following the FDA’s IND clearance of ADI-001 in lupus nephritis,” said ...

High-risk stocks could potentially turn the tables for investors willing to stomach the risk. Moreover, as the Nasdaq Composite hit a fresh high last Friday, ahead of its 2021 peak, the market’s appetite for risk continues to grow. The S&P 500’s ascent to 5,137 marks its 15th record closure for the year, underscoring the eagerness among investors to embrace riskier ventures. Hence, this climate is ripe for high-risk stocks that could pay off, provided they are grounded on a robust foundation and present ste ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Adicet Bio, Inc. (ACET) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Adicet Bio, Inc. is a member of the Medical sector. This group includes 1065 individual stocks and currently holds a Zacks Sector Rank of #5. The Zacks Sector Rank considers 16 different groups, me ...

Penny stocks are heating up as the S&P 500 hits new highs, signaling opportunity. With the S&P 500 posting new highs multiple times in the past few months and prospects of lower interest rates, the stage is set for potentially lucrative penny stock investments. However, the stocks in the article stand to benefit not just from favorable macroeconomic trends but also from company-specific catalysts. Moreover, given the uncertainty surrounding rate cuts, it is imperative for investors looking to capitalize on ...

While targeting the therapeutic side of the healthcare sector can be quite lucrative, nothing matches the excitement of biotech penny stocks. Of course, the excitement goes toward both extremes of the emotional spectrum.This is a good time to remind you of all the reasons you shouldn’t buy biotech penny stocks. The first reason centers on the last two words. While many of these companies may claim advanced clinical data and whatnot, the reality is that many if not most players in this field will fail. That’ ...